Oxurion (OTCMKTS:TBGNF – Get Rating) is one of 406 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Oxurion to related companies based on the strength of its dividends, earnings, profitability, risk, institutional ownership, analyst recommendations and valuation.
Profitability
This table compares Oxurion and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oxurion | N/A | N/A | N/A |
| Oxurion Competitors | -477.67% | -67.10% | -24.73% |
Insider and Institutional Ownership
11.1% of Oxurion shares are held by institutional investors. Comparatively, 27.9% of shares of all “Biotechnology” companies are held by institutional investors. 23.9% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oxurion | 0 | 0 | 0 | 0 | N/A |
| Oxurion Competitors | 830 | 1971 | 6189 | 80 | 2.61 |
As a group, “Biotechnology” companies have a potential upside of 125.03%. Given Oxurion’s rivals higher possible upside, analysts plainly believe Oxurion has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares Oxurion and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Oxurion | N/A | N/A | -0.12 |
| Oxurion Competitors | $373.71 million | $53.84 million | 19.12 |
Oxurion’s rivals have higher revenue and earnings than Oxurion. Oxurion is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
Oxurion rivals beat Oxurion on 5 of the 8 factors compared.
About Oxurion
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist, which is in Phase II clinical trials for the treatment of DME. Oxurion NV has collaboration agreements with Bicycle Therapeutics and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Receive News & Ratings for Oxurion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxurion and related companies with MarketBeat.com's FREE daily email newsletter.
